Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02638428
Other study ID # 2015-08-008
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date December 2015
Est. completion date December 2023

Study information

Verified date March 2020
Source Samsung Medical Center
Contact Ki Woong Sung, MD, PhD
Phone 82-2-3410-3529
Email kiwoong.sung@samsung.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and feasibility of combination chemotherapy with target agents according to the result of targeted deep sequencing in pediatric patients with relapsed/refractory solid tumor or AML.


Description:

Read more »
Read more »

Study Design


Intervention

Read more »

Locations

Country Name City State
Korea, Republic of Samsung Medical Center Seoul

Sponsors (2)

Lead Sponsor Collaborator
Samsung Medical Center Ministry of Health, Republic of Korea

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Rate of event free survival Event is defined as relapse, disease progression or treatment-related mortality. Up to 5 years
Secondary Rate of treatment-related adverse events as assessed by CTCAE v4.0 Up to 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT04033627 - TCDαβ/CD45RA Haploidentical Transplantation in Children With Leukemia N/A
Completed NCT04562792 - Low Dose Daunorubicin in Pediatric Relapsed/Refractory Acute Leukemia Phase 2
Withdrawn NCT05622591 - ELU001 in Pediatric Subjects Who Have Relapsed and/or Refractory CBFA2T3-GLIS2-positive AML Phase 1
Approved for marketing NCT03245424 - Ivosidenib Expanded Access Program in Relapsed/Refractory AML With an IDH1 Mutation